News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

Cancer Research UK welcomes glioma drug ruling

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)


Posted on: 12/23/2006

Cancer Research UK welcomes glioma drug ruling


The number of patients with glioma - a form of brain tumour - who are eligible to receive temozolomide on the NHS has been increased following an appeal to the National Institute for Health and Clinical Excellence (NICE).

Cancer Research UK, which funded research and phase one and two trials into the drug, welcomed the decision to change the original ruling, which recommended temozolomide only for patients who were fully active.

NICE now recommends that patients who are slightly less active may also be considered for the drug.

"We are very pleased with today's NICE decision which will enable more patients who are diagnosed with high-grade glioma to benefit from temozolomide," said Professor John Toy of Cancer Research UK.

"Because brain cancer can be very difficult to treat successfully, patient access to a drug like temozolomide is particularly important for them.

"We hope this recommendation will be implemented as quickly as possible to give more patients with brain cancer a treatment that extends lives."

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557